Hany Ibrahim: Lp(a) Lowering Meets a Critical Test in the Lp(a)HORIZON Trial
Hany Ibrahim, Vice President of Clinical Strategy at Global Learning Collaborative (GLC), a US Health Connect Company, Associate Professor of Biomedical Education at California Health Sciences University (CHSU), shared a post on LinkedIn:
“Today’s announcement that the topline results from the Phase 3 Lp(a)HORIZON trial showed that it did not meet its primary cardiovascular endpoint is undoubtedly disappointing, particularly given the substantial unmet need among people with elevated lipoprotein(a).
My initial thoughts are:
- Even when extensive genetic and epidemiologic evidence supports a risk factor as causal, lowering it pharmacologically does not automatically guarantee improved clinical outcomes. The magnitude, timing, duration, and mechanism of reduction, as well as the population treated, can all matter.
- This was one study evaluating a specific therapy. The findings cannot yet be assumed to apply uniformly to every Lp(a)-lowering agent or therapeutic modality, although they will undoubtedly have important implications for the entire field.
- The full results will be essential. We need to understand more.
- This result raises the scientific and evidentiary bar for ongoing Lp(a)-lowering trials. Demonstrating profound biomarker reduction will not be enough; a meaningful reduction in cardiovascular events remains the ultimate measure of success.
- This outcome should not diminish the importance of recognizing elevated Lp(a) as a genetically determined and independent cardiovascular risk factor.
This is a sobering result, but not necessarily the end of the Lp(a) story.
It is a reminder that cardiovascular science advances by rigorously testing compelling biological hypotheses against outcomes that truly matter to patients.
Visual disclaimer: The accompanying image is AI-generated conceptual artwork and is not a scientifically accurate representation of the structure of the Lp(a) particle.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning